Display options
Cite
Bogdanov AA, Mazzanti M, Castillo G, et al. Protected Graft Copolymer (PGC) in Imaging and Therapy: A Platform for the Delivery of Covalently and Non-Covalently Bound Drugs. Theranostics. 2012;2(6):553-76doi: 10.7150/thno.4070.
Bogdanov, A. A., Mazzanti, M., Castillo, G., & Bolotin, E. (2012). Protected Graft Copolymer (PGC) in Imaging and Therapy: A Platform for the Delivery of Covalently and Non-Covalently Bound Drugs. Theranostics, 2(6), 553-76. https://doi.org/10.7150/thno.4070
Bogdanov, Alexei A, et al. "Protected Graft Copolymer (PGC) in Imaging and Therapy: A Platform for the Delivery of Covalently and Non-Covalently Bound Drugs." Theranostics vol. 2,6 (2012): 553-76. doi: https://doi.org/10.7150/thno.4070
Bogdanov AA, Mazzanti M, Castillo G, Bolotin E. Protected Graft Copolymer (PGC) in Imaging and Therapy: A Platform for the Delivery of Covalently and Non-Covalently Bound Drugs. Theranostics. 2012;2(6):553-76. doi: 10.7150/thno.4070. Epub 2012 Jun 04. PMID: 22737192; PMCID: PMC3381344.
Copy Download .nbib Format: NLM
Share it on

Theranostics. 2012;2(6):553-76. doi: 10.7150/thno.4070. Epub 2012 Jun 04.

Protected Graft Copolymer (PGC) in Imaging and Therapy: A Platform for the Delivery of Covalently and Non-Covalently Bound Drugs.

Theranostics

Alexei A Bogdanov, Mary Mazzanti, Gerardo Castillo, Elijah Bolotin

Affiliations

  1. 1. University of Massahcusetts Medical School, Worcester MA;

PMID: 22737192 PMCID: PMC3381344 DOI: 10.7150/thno.4070

Abstract

Initially developed in 1992 as an MR imaging agent, the family of protected graft copolymers (PGC) is based on a conjugate of polylysine backbone to which methoxypoly(ethylene glycol) (MPEG) chains are covalently linked in a random fasion via N-ε-amino groups. While PGC is relatively simple in terms of its chemcial composition and structure, it has proved to be a versatile platform for in vivo drug delivery. The advantages of poly amino acid backbone grafting include multiple available linking sites for drug and adaptor molecules. The grafting of PEG chains to PGC does not compromise biodegradability and does not result in measurable toxicity or immunogenicity. In fact, the biocompatablility of PGC has resulted in its being one of the few 100% synthetic non-proteinaceous macromolecules that has suceeded in passing the initial safety phase of clinical trials. PGC is capable of long circulation times after injection into the blood stream and as such found use early on as a carrier system for delivery of paramagnetic imaging compounds for angiography. Other PGC types were later developed for use in nuclear medicine and optical imaging applications in vivo. Recent developments in PGC-based drug carrier formulations include the use of zinc as a bridge between the PGC carrier and zinc-binding proteins and re-engineering of the PGC carrier as a covalent amphiphile that is capabe of binding to hydrophobic residues of small proteins and peptides. At present, PGC-based formulations have been developed and tested in various disease models for: 1) MR imaging local blood circulation in stroke, cancer and diabetes; 2) MR and nuclear imaging of blood volume and vascular permeability in inflammation; 3) optical imaging of proteolytic activity in cancer and inflammation; 4) delivery of platinum(II) compounds for treating cancer; 5) delivery of small proteins and peptides for treating diabetes, obesity and myocardial infarction. This review summarizes the experience accumulated by various research groups that chose to use PGC as a drug delivery platform.

Keywords: chelate; contrast agent; gadolinium.; gaft-copolymer; paramagnetic; poly(ethylene glycol)

References

  1. J Magn Reson Imaging. 1997 Jan-Feb;7(1):102-10 - PubMed
  2. Science. 1993 Jul 9;261(5118):212-5 - PubMed
  3. Obes Rev. 2011 May;12(5):e315-23 - PubMed
  4. Bioconjug Chem. 2004 Nov-Dec;15(6):1403-7 - PubMed
  5. Nature. 1986 Dec 4-10;324(6096):473-6 - PubMed
  6. J Biol Chem. 1977 Jun 10;252(11):3578-81 - PubMed
  7. Biochim Biophys Acta. 1998 May 8;1380(3):354-68 - PubMed
  8. J Control Release. 1998 Jun;54(1):39-48 - PubMed
  9. Magn Reson Med. 1998 Nov;40(5):666-78 - PubMed
  10. Neoplasia. 2002 May-Jun;4(3):228-36 - PubMed
  11. Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6215-9 - PubMed
  12. FASEB J. 2009 Dec;23(12):4126-34 - PubMed
  13. Cancer Res. 2005 Oct 15;65(20):9398-405 - PubMed
  14. Nature. 1995 Nov 2;378(6552):65-8 - PubMed
  15. Mol Endocrinol. 1998 Jul;12(7):962-72 - PubMed
  16. Colloids Surf B Biointerfaces. 2011 Jun 15;85(1):86-91 - PubMed
  17. Annu Rev Cell Biol. 1993;9:541-73 - PubMed
  18. Neoplasia. 2004 Mar-Apr;6(2):95-105 - PubMed
  19. AJR Am J Roentgenol. 1994 May;162(5):1041-6 - PubMed
  20. Eur J Pharm Biopharm. 2000 Jul;50(1):61-81 - PubMed
  21. Circulation. 1992 Dec;86(6 Suppl):III30-42 - PubMed
  22. Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14730-5 - PubMed
  23. Pharm Res. 2012 Jan;29(1):306-18 - PubMed
  24. Diabetes. 2007 Nov;56(11):2677-82 - PubMed
  25. Eur J Cancer. 1998 Aug;34(9):1448-54 - PubMed
  26. Radiology. 1995 Dec;197(3):665-9 - PubMed
  27. Biochim Biophys Acta. 1994 Oct 12;1195(1):11-20 - PubMed
  28. Circulation. 2005 Apr 12;111(14):1800-5 - PubMed
  29. Nature. 1987 Apr 16-22;326(6114):697-8 - PubMed
  30. Circulation. 2002 Dec 3;106(23):2894-900 - PubMed
  31. Handb Exp Pharmacol. 2010;(197):3-53 - PubMed
  32. Adv Drug Deliv Rev. 1999 Apr 5;37(1-3):279-293 - PubMed
  33. JAMA. 1999 Oct 27;282(16):1568-75 - PubMed
  34. Int J Pharm. 2010 Aug 30;396(1-2):219-28 - PubMed
  35. Bioconjug Chem. 1999 Sep-Oct;10(5):892-6 - PubMed
  36. Cancer Res. 2005 Oct 15;65(20):9253-60 - PubMed
  37. Stroke. 1985 Jan-Feb;16(1):101-9 - PubMed
  38. Radiology. 1999 Dec;213(3):866-70 - PubMed
  39. Biochim Biophys Acta. 1985;780(3):167-80 - PubMed
  40. Radiology. 2002 Mar;222(3):814-8 - PubMed
  41. Cancer Chemother Rep. 1966 May;50(4):219-44 - PubMed
  42. Nat Med. 2001 Jun;7(6):743-8 - PubMed
  43. Radiology. 1995 Jul;196(1):239-44 - PubMed
  44. J Control Release. 2009 May 21;136(1):14-20 - PubMed
  45. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):9003-8 - PubMed
  46. Magn Reson Med. 2004 Sep;52(3):485-94 - PubMed
  47. Bioconjug Chem. 1993 Jan-Feb;4(1):54-62 - PubMed
  48. Amino Acids. 2002;23(1-3):301-8 - PubMed
  49. Circulation. 2006 Jul 4;114(1):55-62 - PubMed
  50. J Nucl Med. 1994 Nov;35(11):1880-6 - PubMed
  51. Chem Biol. 2004 Jan;11(1):99-106 - PubMed
  52. J Drug Target. 2007 Jul;15(6):391-8 - PubMed
  53. Stroke. 1999 Oct;30(10):2197-204; discussion 2204-5 - PubMed
  54. Nat Med. 1995 Sep;1(9):953-6 - PubMed
  55. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9238-42 - PubMed
  56. Bioconjug Chem. 1998 Mar-Apr;9(2):184-91 - PubMed
  57. Hum Gene Ther. 1996 Nov 10;7(17):2123-33 - PubMed
  58. Eur J Pharm Sci. 2000 May;10(3):169-77 - PubMed
  59. Lancet. 2007 Oct 27;370(9597):1483-93 - PubMed
  60. Magn Reson Med. 2008 Oct;60(4):813-21 - PubMed
  61. Radiology. 1993 Jun;187(3):701-6 - PubMed
  62. Bone. 2009 Feb;44(2):190-8 - PubMed
  63. Circ Res. 2008 Feb 1;102(2):185-92 - PubMed
  64. Neoplasia. 1999 Nov;1(5):438-45 - PubMed
  65. Adv Enzyme Regul. 2001;41:189-207 - PubMed
  66. Invest Radiol. 1991 Dec;26(12):1035-40 - PubMed
  67. J Biomed Opt. 2006 May-Jun;11(3):34013 - PubMed
  68. Cancer Res. 2006 Jul 15;66(14):7225-9 - PubMed
  69. J Drug Target. 1997;4(5):321-30 - PubMed
  70. Int J Cancer. 1999 Dec 10;83(6):798-802 - PubMed
  71. Science. 1991 Apr 5;252(5002):120-3 - PubMed
  72. Gastroenterology. 2002 Feb;122(2):406-14 - PubMed
  73. Recent Results Cancer Res. 1980;74:132-8 - PubMed
  74. Pharm Res. 2012 Apr;29(4):1033-9 - PubMed
  75. J Cereb Blood Flow Metab. 2005 May;25(5):583-92 - PubMed
  76. Magn Reson Med. 1996 Dec;36(6):858-67 - PubMed
  77. Bioconjug Chem. 1996 Jan-Feb;7(1):144-9 - PubMed
  78. Cardiol Clin. 1996 May;14(2):211-20 - PubMed
  79. Osteoarthritis Cartilage. 2004 Mar;12(3):239-44 - PubMed
  80. Nat Biotechnol. 1999 Apr;17(4):375-8 - PubMed
  81. Biopolymers. 1971;10(4):657-80 - PubMed
  82. J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 - PubMed
  83. Technol Cancer Res Treat. 2002 Dec;1(6):489-95 - PubMed
  84. J Am Pharm Assoc Am Pharm Assoc. 1947 May;36(5):157-60 - PubMed
  85. Gan To Kagaku Ryoho. 1987 Mar;14(3 Pt 2):821-9 - PubMed
  86. Arthritis Rheum. 2004 Aug;50(8):2459-65 - PubMed
  87. Magn Reson Med. 2002 Jun;47(6):1110-20 - PubMed
  88. Circulation. 2002 Jun 11;105(23):2766-71 - PubMed
  89. J Drug Target. 1997;4(6):381-8 - PubMed
  90. AJR Am J Roentgenol. 1998 Jul;171(1):137-43 - PubMed

Publication Types

Grant support